Literature DB >> 3401075

Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups.

W R Jamieson1, L J Rosado, A I Munro, A N Gerein, L H Burr, R T Miyagishima, M T Janusz, G F Tyers.   

Abstract

Primary tissue failure (structural valve deterioration) has been documented as the most prominent complication of porcine bioprostheses. The influence of age on primary tissue failure has received limited consideration. From 1975 to 1986, 1,301 Carpentier-Edwards standard porcine bioprostheses were implanted in 1,183 patients in 1,201 operations. Of the total number of prostheses, 97.7% were implanted prior to 1983. The mean follow-up was 5.6 years and was 97.5% complete. Primary tissue failure was identified in 96 patients (98 operations) at reoperation (95) or autopsy (3). One hundred four (104) prostheses were involved. Thirty-one failed after aortic valve replacement (AVR), 49 after mitral valve replacement (MVR), and 24 after multiple-valve replacement (18 patients). There were 47 male and 49 female patients. The mean age at implantation was 47 years (range, 8 to 72 years). The mean implantation time was 74.0 months. The freedom from primary tissue failure at 10 years is 77.0 +/- 2.9% overall; for AVR, 83.1 +/- 3.7%; for MVR, 72.1 +/- 4.9%; and for multiple-valve replacement, 65.5 +/- 7.8%. The freedom from deterioration for patients less than 20 years of age is significantly less than that for other age groups. The freedom from deterioration increased by decades; the greatest freedom was noted in patients 70 to 80 years old and 80 years old or older. The freedom from deterioration at 10 years for patients less than 30 years of age is 26.8 +/- 17.2%; 30 to 59 years, 77.4 +/- 3.0%; and 60 years and older, 83.1 +/- 4.2%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3401075     DOI: 10.1016/s0003-4975(10)65888-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

1.  Comparison of multicenter registries and randomized control trials for transcatheter aortic valve replacement (TAVR).

Authors:  Shikhar Agarwal; E Murat Tuzcu; William Stewart; Navkaranbir Singh Bajaj; Lars G Svensson; Samir R Kapadia
Journal:  Indian Heart J       Date:  2013-07-10

2.  Reconstruction of bicuspid aortic valves. Surgical tool or toy?

Authors:  H-J Schäfers
Journal:  Z Kardiol       Date:  2005-07

Review 3.  Prosthetic valve selection for middle-aged patients with aortic stenosis.

Authors:  Joanna Chikwe; Farzan Filsoufi; Alain F Carpentier
Journal:  Nat Rev Cardiol       Date:  2010-11-02       Impact factor: 32.419

4.  Good outcomes from cardiac surgery in the over 70s.

Authors:  A M Zaidi; A P Fitzpatrick; D J Keenan; N J Odom; G J Grotte
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

5.  Clinical results of the Pop De Popa xenobioprosthesis in patients with advanced heart failure: long-term follow-up of 562 patients.

Authors:  I P De Popa; D Gherghiceanu; M Bârsan; C Macarie; I Socoteanu; T Petrila; F Bradu; R Fagarasanu; L Panta
Journal:  Tex Heart Inst J       Date:  1992

6.  Double valve Implantation. Long-term evaluation of 8 different bioprostheses.

Authors:  P Stassano; V Mannacio; A Musumeci; A Golino; P Maida; V Ferrigno; G Buonocore; N Spampinato
Journal:  Tex Heart Inst J       Date:  1991

Review 7.  Prosthetic heart valves and management during pregnancy.

Authors:  Farida Mary Jeejeebhoy
Journal:  Can Fam Physician       Date:  2009-02       Impact factor: 3.275

Review 8.  Valvular Heart Disease and Pregnancy.

Authors:  Emily S Lau; Nandita S Scott
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-26

Review 9.  Anticoagulation during pregnancy in patients with a prosthetic heart valve.

Authors:  Jose M Castellano; Rajeev L Narayan; Prashant Vaishnava; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2012-05-15       Impact factor: 32.419

10.  Removal of alpha-Gal epitopes from porcine aortic valve and pericardium using recombinant human alpha galactosidase A.

Authors:  Seongsik Park; Woong-Han Kim; Sun-Young Choi; Yong-Jin Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.